Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq of HNF4A, PPARGC1A and H3K27ac in oesophageal adenocarcinoma OE19 cells treated with lapatinib

ABSTRACT: ChIP-seq for HNF4A, PPARGC1A and H3K27ac was performed in OE19 cells to identify genomic binding sites. Cells were treated with DMSO or 500 nM lapatinib for 48 hours.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Homo sapiens

SUBMITTER: Samuel Ogden

PROVIDER: E-MTAB-10319 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

ChIP-seq of PPARGC1A in oesophageal adenocarcinoma OE19 cells treated with lapatinib

Project description:ChIP-seq for PPARGC1A was performed in OE19 cells to identify genomic binding sites. Cells were treated with 500 nM lapatinib for 48 hours.

2022-09-26 | E-MTAB-11300 | biostudies-arrayexpress

RNA-seq of human oesophageal adenocarcinoma OE19 cell line following PPARGC1A knock-down and 24 hour lapatinib treatment

Project description:To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with either DMSO or 500 nM lapatinib for 24 hours.

2022-09-26 | E-MTAB-10317 | biostudies-arrayexpress

RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10304 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10302 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal

Project description:To investigate whether changes to chromatin accessibility associated with resistance to lapatinib are a stable or a reversible state, we treated OE19 cells with 500 nM lapatinib for 35 days and then withdrew lapatinib for 1, 2, 3 and 14 days. Control cells treated with DMSO for 1 day and 'resistant' cells treated with 500 nM lapatinib for 35 days were also sequenced.

2022-09-26 | E-MTAB-10314 | biostudies-arrayexpress

ChIP-seq of HNF4A and GATA6 in oesophageal adenocaricnoma OE19 cells

Project description:The genome-wide binding sites of transcription factors provide insight into their regulatory function. We used chromatin immunoprecipitaition with high-throughput sequencing (ChIP-seq) to identify the genomic binding sites of HNF4A and GATA6 in OE19 cells.

2019-02-09 | E-MTAB-6858 | biostudies-arrayexpress

ChIP-seq of HNF4A and GATA6 in oesophageal adenocaricnoma OE19 cells

Project description:ChIP-seq of HNF4A and GATA6 in oesophageal adenocaricnoma OE19 cells

| PRJEB35342 | ENA

HiC data of the human oesophageal adenocarcinoma (EAC) cell lines OE19

Project description:This dataset consists of in situ HiC-seq data from a human oesophageal adenocarcinoma cell line (OE19). In total, the dataset includes 2 biological replicated samples. The Hi-C sample and library preparations were generated using Arima-HiC Kit (A510008, ARIMA Genomics) and Arima Library Prep module (A303011, ARIMA Genomics), respectively.

2023-02-20 | E-MTAB-12664 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma KYAE1 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on KYAE1 cells treated with 500 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10310 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma ESO26 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on ESO26 cells treated with 500 nM lapatinib plus 1000 nM MK-2206 (an AKT inhibitor) for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10307 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data